Can we improve patient selection for phase I clinical trials (phI1) based on immuno-oncology score prognostic index (VIO)?
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz239.046
Abstract: Abstract Background Life expectancy longer than 12 weeks(w) is a common inclusion criteria for most Ph1. Despite the presence of several prognostic indeces in drug development, their value for patient selection in clinical trials is… read more here.
Keywords: bristol myers; advisory consultancy; oncology; roche ... See more keywords
Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): A French nationwide retrospective cohort (UNIVOC Study)
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz253.106
Abstract: Abstract Background Nivolumab demonstrated superior overall survival (OS) in clinical trials compared to docetaxel in patients previously treated for squamous (Sq) and non-squamous (NSq) aNSCLC. The objective was to describe in French real-world setting the… read more here.
Keywords: treatment; bristol myers; cohort; myers squibb ... See more keywords
Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: A network meta-analysis
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz255.036
Abstract: Abstract Background Targeted and checkpoint inhibitor therapies for advanced melanoma have led to major improvements in overall survival (OS). Using long-term evidence, the objective was to estimate the relative efficacy of nivolumab plus ipilimumab (NIVO+IPI)… read more here.
Keywords: time; bristol myers; precision xtract; precision ... See more keywords
Cost of adverse events (AEs) with second-line (2L) immuno-oncology agents (IO) and chemotherapy (CHEMO) in advanced non-small cell lung cancer (aNSCLC) in the real-world
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz449.028
Abstract: Abstract Background Randomized clinical trials in aNSCLC demonstrated that 2L IO prolonged overall survival and lowered AE rates compared with 2L CHEMO. However, real-world (RW) evidence from clinical practice is limited, and the potential cost… read more here.
Keywords: chemo; cost; bristol myers; oncology ... See more keywords
AB0267 Treatment paradigms in real-world practice: biologic agent use prior to and after discontinuation of abatacept in the action study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1392
Abstract: Background ACTION is a 2-year, observational study of patients (pts) with moderate-to-severe RA who initiated IV abatacept (ABA) in Canada and Europe (NCT02109666). Objectives To determine pt biologic (b)DMARD use prior to initiation and after… read more here.
Keywords: discontinuation; biologic failure; myers squibb; bristol myers ... See more keywords
OP0223 Abatacept in the treatment of active psoriatic arthritis: 1-year results from a phase iii study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.2865
Abstract: Background In the Phase III ASTRAEA trial (NCT01860976), abatacept (ABA), a selective T-cell co-stimulation modulator, significantly increased ACR20 response (primary endpoint; PE) and had an overall beneficial effect vs placebo (PBO) on musculoskeletal symptoms in… read more here.
Keywords: pfizer; pbo; bristol myers; aba ... See more keywords
OP0010 Use of claims and electronic medical record data to predict ra disease activity
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2047
Abstract: Background Prior studies have demonstrated challenges in developing and validating claims-based algorithms that accurately predict RA disease activity.1 2 The ability to adjust for and predict RA disease activity would be a powerful epidemiological tool… read more here.
Keywords: emr data; bristol myers; disease activity; activity ... See more keywords
SAT0330 Changes in lymphocytes and lymphocyte subsets in tofacitinib-treated patients with psoriatic arthritis
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.3490
Abstract: Background Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of psoriatic arthritis (PsA). Cytokines involved in lymphocyte development, function and homeostasis signal through JAKs, and reductions in mean lymphocyte count over time… read more here.
Keywords: pfizer; pfizer inc; bristol myers; eli lilly ... See more keywords
THU0190 THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BMS-986166, A NOVEL, SELECTIVE, PARTIAL AGONIST OF THE SPHINGOSINE-1-PHOSPHATE (S1P) SUBTYPE 1 RECEPTOR IN HEALTHY PARTICIPANTS
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.1967
Abstract: Background S1P mediates a number of immune processes including the egress of lymphocytes from lymphoid organs via stimulation of the S1P subtype 1 receptor (S1P1R). S1P1R inhibition has the potential to suppress abnormal immune responses… read more here.
Keywords: employee bristol; bms 986166; myers squibb; bristol myers ... See more keywords
SAT0179 CHANGE IN IMMUNOLOGICAL PARAMETERS DURING FOLLOW-UP OF PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME: DATA FROM THE FRENCH ASSESS COHORT
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.2241
Abstract: Background Primary Sjögren’s Syndrome (pSS) is associated with a biological panel of B-cell activity markers such as hypergammaglobulinemia, rheumatoid factor (RF), decreased C3/C4 complement, cryoglobulinemia, and an increase in β2-microglobulin, used to calculate the biological… read more here.
Keywords: gren syndrome; change; bristol myers; primary gren ... See more keywords
OP0056 MAINTENANCE OF CLINICAL RESPONSE IN INDIVIDUAL CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH SUBCUTANEOUS ABATACEPT
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.236
Abstract: Background The efficacy of SC abatacept (ABA) in patients (pts) with polyarticular-course juvenile idiopathic arthritis (pJIA) was shown in a 2-year (yr), Phase III, open-label international study (NCT01844518).1 However, it is unknown whether each individual… read more here.
Keywords: response; myers squibb; bristol myers; research ... See more keywords